Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

Phase 1 Terminated 7 enrolled Par Pharmaceutical, Inc. Covance · collab SFBC Anapharm · collab

Non-randomizedParallel-groupOpen-label

Summary

To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment

Timeline

Start: 2006-05
Primary completion: 2006-05
Completion: 2006-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Megestrol Acetate	Other / unclassified	300 mg	Oral

Indications

No indication recorded.